Exondys 51 Market 2026–2035 advancing Duchenne muscular dystrophy therapies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Exondys 51 Market By The End Of 2030?

The expansion observed during prior periods was due to the absence of curative DMD therapies, a long-standing dependence on supportive care methods, pioneering antisense research efforts, incentives for developing treatments for rare diseases, and the initial granting of regulatory approvals.

The anticipated growth throughout the forecast period is fueled by advancements in molecular genetics, the expansion of individualized neuromuscular care, a surge in newborn screening initiatives, increased investment in Duchenne muscular dystrophy research, and the emergence of more specialty neurology centers. Concurrently, major developments during this period are expected to encompass the rise of exon skipping treatments, broader access to targeted therapies for Duchenne muscular dystrophy, increasing adoption of genetic-based medications, a heightened focus on slowing the disease’s progression, and improved management of long-term treatment regimens.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20071&type=smp

What Drivers Are Shaping The Future Growth Of The Exondys 51 Market?

The increasing prevalence of genetic disorders is anticipated to stimulate the expansion of the exondys 51 market. Genetic disorders are health conditions resulting from anomalies or mutations within an individual’s DNA or genetic makeup. This growing burden of such disorders stems from various factors, including breakthroughs in medical technology, shifts in demographics, and enhanced diagnostic capabilities and public awareness. Exondys 51 (eteplirsen) addresses these conditions by facilitating exon 51 skipping in the dystrophin gene, which enables the creation of a functional, albeit shorter, dystrophin protein to impede muscle degeneration. As an illustration, in July 2024, the National Health Service, a UK-based government department, reported that around 70,000 individuals in the UK are impacted by muscular dystrophy (MD) or related conditions, with Duchenne MD being the most common. Annually, approximately 100 boys receive a Duchenne MD diagnosis, and about 2,500 people in the UK are currently living with this condition. Consequently, the escalating burden of genetic disorders is propelling the growth of the exondys 51 market.

Which Segment Classifications Shape The Exondys 51 Market?

The exondys 51 market covered in this report is segmented –

1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms

2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies

3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use

How Are Trends Impacting The Exondys 51 Market?

Major companies in the exondys 51 market are increasingly focusing on boosting safety and optimizing patient selection, which includes updating prescribing information for ELEVIDYS to mitigate liver-related risks and ensure appropriate patient eligibility. ELEVIDYS refers to Sarepta Therapeutics’ AAV-based micro-dystrophin gene therapy (delandistrogene moxeparvovec), created to restore dystrophin expression in patients with Duchenne muscular dystrophy (DMD). For instance, in November 2025, the U.S. FDA, a US-based federal agency, approved a revised label for ELEVIDYS, which added a boxed warning for acute serious liver injury and acute liver failure and limited its use to ambulatory patients aged four years and older. The update requires mandatory weekly liver-function testing for the first three months post-infusion, necessitates corticosteroid pre- and post-dosing, and advises patients to remain near a qualified healthcare facility for at least two months, all aimed at enhancing safety monitoring and improving patient outcomes.

Which Companies Are Expanding Their Footprint In The Exondys 51 Market?

Major companies operating in the exondys 51 market are Sarepta Therapeutics

Read the full exondys 51 market report here:

https://www.thebusinessresearchcompany.com/report/exondys-51-global-market-report

Which Geographic Regions Are Influencing Demand In The Exondys 51 Market?

North America was the largest region in the exondys 51 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the exondys 51 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Exondys 51 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20071&type=smp

Browse Through More Reports Similar to the Global Exondys 51 Market 2026, By The Business Research Company

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Esg Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/esg-finance-global-market-report

Smart Finance Hardware Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-finance-hardware-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795